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Objectives: To evaluate the impact of one oral dose of intrapartum azithromycin (2 g) on the carriage and anti-
biotic resistance of Escherichia coli and Klebsiella pneumoniae in the nasopharynx, breast milk and vaginal swabs
of mothers and K. pneumoniae in the nasopharynx of their newborns.
Methods: We performed a post hoc analysis of a double-blind, placebo-controlled randomized-trial (ratio 1:1)
conducted in The Gambia. Breast milk (BM) and vaginal swabs (VS) from mothers and nasopharyngeal swabs
(NPS) from mother–newborn pairs were collected at different timepoints during the 4 week follow-up. Samples
were processed using standard microbiological procedures. For BM and NPS post-intervention results were com-
bined for analysis.
Results: In the original trial 829 mothers were randomized. In this analysis, complete sample sets were avail-
able for 630 mothers for E. coli analysis (76.0%) and 564 mother–newborn pairs for K. pneumoniae analysis
(68.0%). For E. coli, carriage prevalence in BM and VS was similar in both arms but resistance was higher in the
azithromycin arm in VS (2.6% versus 0%, P"0.004). For K. pneumoniae, carriage prevalence was higher in the
azithromycin arm for BM (13.8% versus 8.7%, P"0.055) but not for VS or NPS. Prevalence of azithromycin resist-
ant K. pneumoniae was higher in the azithromycin arm for BM (3.6% versus 1.0%, P"0.050) and VS (1.5% versus
0% P"0.057).
Conclusions: Oral intrapartum azithromycin did not reduce carriage of E. coli and K. pneumoniae and was associa-
ted with an increase in the prevalence of azithromycin-resistant E. coli and K. pneumoniae isolates in BM and VS.
Introduction
Despite substantial efforts to reduce worldwide neonatal mortal-
ity, it remains unacceptably high, with up to 2.5 million deaths per
year. The greatest mortality burden falls on low- and middle-
income countries, with countries in West and Central Africa, and
South Asia having the highest rates in 2017.1 Infections, mostly
sepsis and meningitis, account for one-third of these deaths.2
Both Gram-positive and Gram-negative bacteria are respon-
sible for neonatal sepsis in sub-Saharan Africa, with recent data
pointing to Staphylococcus aureus as the most common causative
agent, closely followed by Enterobacterales, i.e. Escherichia coli
and Klebsiella spp.3 Antimicrobial resistance (AMR) in S. aureus is
relatively low on the African continent, but AMR particularly to
ampicillin and gentamicin (antibiotics recommended by WHO for
the treatment of neonatal sepsis) is much higher for E. coli and
Klebsiella spp.3 The most clinically significant Klebsiella species is
Klebsiella pneumoniae because of its higher prevalence.
Furthermore, its role together with E. coli, in hospital- and
community-acquired infections is alarming,3–5 as they may har-
bour genes that confer resistance to b-lactam antibiotics, fluoro-
quinolones and aminoglycosides that are carried on transferable
mobile genetic elements.6 Infections with MDR Enterobacterales
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are particularly difficult to treat and are associated with poor
outcomes.7
Context-specific interventions aimed at reducing the high
burden of neonatal sepsis are urgently needed in sub-Saharan
Africa. We conducted a double-blind randomized trial (PregnAnZI)
to assess the effect of one oral dose of intrapartum azithromycin
(2 g) on bacterial carriage of the main Gram-positive pathogens
associated with neonatal sepsis [S. aureus, Streptococcus pneumo-
niae and Group B Streptococcus, (GBS)] in the mother and the new-
born during the 4 weeks following treatment.8 The trial showed a
reduction of bacterial carriage of these three bacteria in both the
mothers and their newborns during the entire neonatal period
and lower occurrence of clinical disease in treated mothers
(i.e. mastitis, sepsis and fever) and their newborns (i.e. skin sepsis
and overall infections) during the 8 weeks following the
intervention.9
In order to further assess the effect of intrapartum azithromy-
cin on the risk of sepsis, here, we evaluate its effect on the
prevalence of carriage and antibiotic resistance of E. coli and
K. pneumoniae in mothers and K. pneumoniae in their newborns
during the 4 weeks following the intervention.
Patients and methods
Study site
The study was conducted at the Bundung Maternal and Child Health
Hospital [formerly known as Jammeh Foundation for Peace (JFP)], a
government-run health centre located in western Gambia that manages
4500 deliveries each year. The population in the catchment area is repre-
sentative of The Gambia and covers the main ethnic groups. Approximately
63% of deliveries in the country occur in health facilities.10 The climate of
the area is typical of the sub-Sahel region, with a dry (January–June) and
wet season (July–December). Illiteracy is high.11
Trial design
The original trial was a double-blind, placebo-controlled randomized
trial in which women attending the study health facility in labour were
randomized to receive a single dose of oral azithromycin (2 g) or pla-
cebo (ratio 1:1).12 Women aged 18–45 years with no acute or chronic
conditions were recruited between April 2013 and April 2014 when
attending JFP labour ward. The women had provided written informed
consent to participate in the study during previous antenatal care visits.
Women and their newborns were followed for up to 8 weeks postpar-
tum and biological samples were collected during the first 4 weeks.8,12
Further details of the trial are reported elsewhere. 12 Clinical Trials regis-
tration: NCT01800942.
Trial samples
Pre-intervention samples [nasopharyngeal swab (NPS) and vaginal swab
(VS)] were collected at the study health facility during labour and before
the intervention was administered. An NPS was collected from the newborn
within 6 h of birth. After discharge, NPS (mothers and babies) and breast
milk samples were collected at days 3, 6, 14 and 28. In addition, a VS was
collected between days 8 and 10 after delivery at the postnatal checkup
visit that took place at the health facility. Details of sample collection can be
found in the study protocol.12
An NPS was also collected at an additional visit (outside of trial follow-
up period) for study infants at the age of 11–13 months.
Ethics approval
A local safety monitor (LSM) and a data safety monitoring board (DSMB)
reviewed serious adverse events during the trial, and the trial was moni-
tored by an independent clinical trials monitor. The trial and the 12 months
follow-up study were approved by the joint Gambia Government/Medical
Research Council (MRC) Ethics committee.
Trial status
The trial had been completed at the time of submission of this manuscript.
Sample handling and laboratory methods
All the field and lab staff were blinded to the participant trial arm. NPS were
collected using a calcium alginate swab that was inserted that was inserted
to the posterior wall of the nasopharynx. The swab was rotated and left in
the nasopharynx for approximately 5 s and then placed in a vial containing
skim milk/tryptone/glucose/glycerol transport medium. The vial containing
the inoculum was put into a cold box and transported to MRC laboratories
within 8 h. Low VS were collected using a sterile cotton swab inserted
2–3 cm into the vagina. The swab was rotated and left in the vagina for
approximately 5 s. The inoculated swabs were then immediately placed
into vials containing skim milk/tryptone/glucose/glycerol, put in a cold box
and transported to MRC laboratories within 8 h. For breast milk (BM) sam-
ples, the nipple and areola were disinfected using sterile cotton soaked with
0.02% chlorhexidine. Mothers were asked to manually express their milk, of
which the first 0.5 mL was discarded and the following 1–2 mL collected in
another sterile bijoux bottle. This were put in a cold box and transported to
MRC laboratories within 8 h.12
On arrival in the laboratory, samples were vortexed for 20 s and stored
at #70C for batch processing. During processing, samples were first
thawed on ice and then vortexed briefly to homogenize the medium. An ali-
quot of 50lL was dispensed onto MacConkey agar (Oxoid, UK) and streaked
for the selective isolation of E. coli and K. pneumoniae.
E. coli was isolated from mothers’ BM and VS while K. pneumoniae was
isolated from these sample types in addition to mothers and newborns
NPS.
Identification of E. coli and K. pneumoniae
After 20–24 h of incubation at 37C, MacConkey plates were examined for
growth of lactose-fermenting smooth pink colonies, presumptive for E. coli.
Three to five suspected colonies were sub-cultured on blood agar and
tested using Kovac’s indole test to differentiate E. coli from other lactose
fermenters. Lactose-positive and indole-positive isolates were confirmed
to be E. coli. Presence of mucoid, pink colonies was presumptive for
K. pneumoniae. Three to five suspected colonies were sub-cultured on
blood agar and subjected to biochemical testing using the rapid API 20E kit
(bioMérieux, France) for the identification of K. pneumoniae.
Antibiotic susceptibility
Well-isolated colonies of E. coli or K. pneumoniae were transferred to
2.5 mL of sterile physiological saline to achieve turbidity of 0.5
MacFarland standard. A sterile swab that had been immersed into the
suspension was streaked onto the surface of Mueller Hinton agar
(Oxoid, UK) in three directions, rotating the plate at 90 angles to ensure
even distribution. Azithromycin susceptibility was tested using disc
diffusion (15 lg azithromycin disc) and the MICs of intermediate and
resistant isolates were determined by Etest according to the CLSI
guidelines.13 CLSI do not have clinical break points for azithromycin
resistance in E. coli and K. pneumoniae, consequently isolates with MICs
32 mg/L were considered resistant based on epidemiological cutoff




The data were double entered into Open Clinica and analysed using
Stata 14. Only mothers from whom VS and BM samples were collected at
all visits were included in the E. coli analysis. If in addition they and their
newborns had NPS collected at all timepoints, the pair was included in the
K. pneumoniae analysis. For each sample type, post-intervention carriage
was considered if any of the post-intervention samples were positive. In
addition, we also calculated the prevalence of carriage at each timepoint.
Prevalence between arms was compared using prevalence ratios (PR) with
their corresponding 95% CIs. We used the v2 test to obtain P values for the
prevalence of carriage and Fisher’s exact test for P values for the prevalence
of resistance. For the post-intervention K. pneumoniae carriage analysis of
the VS, we adjusted for the observed baseline imbalance using Poisson re-
gression with robust standard errors. The statistical analysis was conducted
using Stata version 13.1.
Results
Study population
Eight hundred and twenty-nine women were recruited into the
trial (n"414 in the azithromycin arm and n"415 in the placebo
arm). These women delivered 843 newborns, including 13 still-
births. Overall, 630 (76% of 829) and 564 (68% of 829) of mother–
newborn pairs had all study samples collected and are part of this
post hoc analysis for E. coli and K. pneumoniae respectively
(Figure 1). Details of baseline characteristics of the participants
included are shown in Table 1.
Prevalence of E. coli carriage and resistance
Prevalence of carriage
For the study women, prevalence of E. coli carriage between study
arms was similar in both BM and VS. Overall post-intervention car-
riage was higher in VS compared with BM (15.5% versus 5.1%)
(Table 2). Details of prevalence of carriage by trial arm at each visit
are shown in Figure 2(a and b).
Prevalence of resistance
Prevalence of E. coli isolates resistant to azithromycin post-
intervention was higher in the azithromycin arm only for the VS
(2.6% versus 0% P"0.004) (Table 2). Details of prevalence
of azithromycin-resistant isolates at each visit are shown in
Figure 2(c and d).
Prevalence of K. pneumoniaeK. pneumoniae carriage
and resistance
Prevalence of carriage
For the study women, post-intervention prevalence of K. pneumo-
niae carriage was similar between arms for NPS (Table 3) but
higher in the azithromycin arm for BM [13.8% versus 8.7%
PR"1.59, 95% CI 0.98–2.56) P"0.055] and VS (5.8% versus 1.4%
PR"4.17, 95% CI 1.41–12.33, P"0.004). However, pre-
intervention prevalence of carriage in the VS was already higher in
the azithromycin arm (4.0% versus 1.4% PR"2.87, 95% CI 0.92–
8.90, P"0.055) and after adjusting for this baseline imbalance,
the difference was not significant (PR"3.11, 95% CI 0.82–11.84,
P"0.095). Details of prevalence of carriage by trial arm at each
visit are shown in Figure 3(a-d).
For newborns, there was a non-significant trend of higher
prevalence in the NPS for K. pneumoniae in the azithromycin arm
compared with the placebo arm (Table 3). Comparisons at 1 year
were not possible because there was no K. pneumoniae isolated
from infants’ NPS at this timepoint.
Prevalence of resistance
For study women, post-intervention prevalence of carriage of
K. pneumoniae azithromycin resistant isolates was very low. It was
similar for both arms in the nasopharynx, but higher in the azithro-
mycin arm for both BM (3.6% versus 1.0% PR"3.48 (0.97–12.51)
P"0.050) and VS (1.5% versus 0% P"0.057). Details of preva-
lence of azithromycin-resistant isolates at each visit are shown
in Figure 3(e-h). For newborns, nasopharyngeal carriage of
Figure 1. Study profile. Abbreviations: m, mothers, nb, newborns. Footnotes: aMothers with 1 missing sample; bSamples from mothers; cMother–
newborn pairs with1 missing sample; dSamples from mothers and newborns.
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Table 1. Baseline characteristics of study participants
Characteristics
K. pneumoniae E. coli
Azithromycin Placebo Azithromycin Placebo
Mothers n"276 n"288 n"313 n"317
Age, months, median (IQR)a 26.0 (22.0–30.0) 26.0 (22.0–30.0) 26.0 (22.0–30.0) 26.0 (22.0–29.0)
Ethnicity, n (%)
Mandinka 104 (37.7) 126 (43.8) 119 (38) 143 (41.5)
Wollof 37 (13.4) 38 (13.2) 41 (13.1) 40 (12.6)
Jola 50 (18.1) 40 (13.9) 53 (16.9) 42 (13.2)
Fula 49 (17.8) 47 (16.3) 60 (19.2) 51 (16.1)
Other 34 (12.3) 37 (12.8) 38 (12.1) 41 (12.9)
Season of deliveryb, n (%)
Dry 182 (65.9) 200 (69.4) 203 (64.9) 215 (67.8)
Rainy 94 (34.1) 88 (30.6) 110 (35.1) 102 (32.2)
Mode of delivery, n (%)
Vaginal 276 (100) 288 (100) 313 (100) 317 (100)
Multiple pregnancy, n (%) 2 (0.72) 4 (1.39) 3 (1.0) 7 (2.2)
Time from treatment to delivery,
hours, median (IQR)
3.2 (1.1–8.3) 2.9 (1.3–6.3) 3.2 (1.1–8.3) 2.9 (1.3–6.3)
Time from rupture of membrane
to delivery, hours, median (IQR)
0.4 (0.1–1.8) 0.3 (0.1–1.3) 0.4 (0.1–1.8) 0.3 (0.1–1.3)
Newbornsc n"276 n"288
Gender, n (%)
Females 138 (50) 132 (45.8)
Males 138 (50) 156 (54.2)
Gestational age, months, (IQR) 36.0 (34.0–38.0) 36.0 (35.0–38.0)
Weight, kg, median (IQR) 3.1 (2.8–3.5) 3.1 (2.9–3.4)
aAge missing in n"3.
bDry season in The Gambia is November to May and Rainy season is June to October.
cOnly K. pneumoniae was isolated from babies (NPS).






(95% CI) P value
Prevalence of carriage
Breast milk
Posta 17 (5.4) 16 (5.1) 1.08 (0.55–2.09) 0.828
Vaginal swab
Preb 43 (13.7) 29 (9.2) 1.50 (0.96–2.34) 0.070
Postc 38 (12.1) 49 (15.5) 0.79 (0.53–1.16) 0.227
Prevalence of carriage of resistant isolates
Breast milk
Posta 2 (0.6) 1 (0.3) 2.03 (0.18–22.22) 0.622
Vaginal swab
Preb 1 (0.3) 0 – 0.497
Postc 8 (2.6) 0 – 0.004
PR, prevalence ratio. P values from v2 test for prevalence of carriage and Fisher’s exact test for prevalence of resistance.
aCumulative incidence of carriage/resistance, i.e. proportion positive at one or more post-treatment visits (days 3, 6, 14 and 28).
bIncidence of carriage/resistance at day 0.
cIncidence of carriage/resistance at day 8.
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K. pneumoniae azithromycin resistance was also low and similar in
both arms (Table 3).
Discussion
One oral dose (2 g) of intrapartum azithromycin did not reduce
the carriage of the most common Gram-negative pathogens
associated with neonatal sepsis, namely E. coli and K. pneumoniae,
during the 4 weeks following the intervention; rather,
K. pneumoniae prevalence increased significantly in BM and VS.
In addition, prevalence of carriage of azithromycin-resistant E. coli
and K. pneumoniae isolates increased, at least in the short term.
Although we had previously shown that intrapartum azithro-
mycin significantly reduces the carriage of Gram-positive bac-
teria,8 the effect of the intervention on Gram-negative organisms
had not been evaluated. The lack of effect on E. coli and
K. pneumoniae carriage in all sample types is consistent with mac-
rolides not being effective against most Enterobacterales, except
for Salmonella and Shigella spp., owing to poor membrane
permeability.14,15 A small study reported azithromycin to be ef-
fective against a pathogenic strain of E. coli when administered in
combination with eculizumab and meningococcal vaccine in
patients with haemolytic uraemic syndrome (HUS).16 Similarly, its
effectiveness against K. pneumoniae is achieved only as adjunctive
treatment.17
Data on the effect of azithromycin on the carriage of other
Gram-negative bacteria, besides Enterobacterales, is also scarce. A
small trial conducted in The Gambia showed that azithromycin
20 mg/kg administered on days 0, 7 and 14 had no effect on
the oropharyngeal carriage of Haemophilus influenzae.18 A trial
conducted in Texas, USA, showed a non-significant decrease in
the nasopharyngeal carriage of H. influenzae, from 32% to 23%, in
children with acute otitis media after azithromycin treatment.19 In
our intrapartum azithromycin trial, we had shown a non-
significant (probably because of low power) reduction of Gram-
negative neonatal conjunctivitis.20
Our data also shows an increase of azithromycin resistance in


































































Figure 2. E. coli prevalence of carriage at different timepoints: (a) Breast milk carriage. (b) Vaginal carriage. (c) Breast milk resistance. (d) Vaginal
resistance.
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VS. A possible explanation would be that although azithromycin
reaches the vagina, it is ineffective for the reduction of carriage
of these bacteria but still has the potential to select for resist-
ance. A similar increase of resistance in the vaginal tract above
the other biological sites was also observed in the main trial for
S. aureus and Group A streptococci. K. pneumoniae resistance
increased also in the BM, where we had previously shown a high
concentration of azithromycin during the 4 weeks following
the intervention.21 Such an increase in resistance had not
been observed for previously studied Gram positives, in which
we rather observed a major decrease in carriage without an
increase in resistance. We did not observe any short-term in-
crease of resistance in the Enterobacterales isolated from NPS
from women in the study.
The prevalence of carriage of K. pneumoniae was not signifi-
cantly different between arms in NPS from newborns, nor did
we observe any increase in resistance from NPS isolated from
newborns. We could not evaluate the long-term effects of the
intervention on newborns because all NPS collected 12 months
after the intervention were negative for K. pneumoniae.
There is a scarcity of data assessing the effect of prophylactic
azithromycin on resistance in Gram-negative bacteria. In
Tanzania, a follow-up study of a mass drug administration (MDA)
of a single dose of oral azithromycin (20 mg/kg) in children aged
between 6 months and 3 years evaluated antimicrobial resistance
in E. coli isolated from rectal swabs. Resistance increased from
10% at baseline to 44% after the first month post-treatment,
and then decreased to 23%, a figure still above the baseline
levels.22 For Gram-positive bacteria, the effect on resistance
seems to be dependent on the level of resistance at baseline,23
but data are lacking for a baseline resistance of ,10% in
Gram-negative bacteria. The effect on the gut could not be
investigated in our study due to limitations of sample type.
However, the possibility of sustained selective pressure with
repeated administration as shown in another Tanzanian study
4 years following four rounds of annual azithromycin MDA,
where E. coli resistance was at 16.6% (107/644), suggests a
need for continuous monitoring.23
The study was designed to investigate the impact of the
intervention on the main Gram-positive bacteria causing neonatal
sepsis and was therefore underpowered to analyse its effect on
Gram-negative bacteria as they have lower prevalence in the
analysed samples. To increase such power, we based the analysis
of Enterobacterales on a combined prevalence of carriage at any







(95% CI) P value
Prevalence of carriage
Maternal NPS
Prea 3 (1.1) 2 (0.7) 1.57 (0.26–9.30) 0.619
Postb 12 (4.4) 16 (5.6) 0.78 (0.38–1.62) 0.509
Breast milk
Postb 38 (13.8) 25 (8.7) 1.59 (0.98–2.56) 0.055
Vaginal swab
Prea 11 (4.0) 4 (1.4) 2.87 (0.92–8.90) 0.055
Postc 16 (5.8) 4 (1.4) 4.17 (1.41–12.33) 0.004e
Neonatal NPS
Postd 41 (14.9) 31 (10.8) 1.38 (0.89–2.13) 0.145
Prevalence of carriage of resistant isolates
Maternal NPS
Prea 0 0 0 0
Postb 0 1 (0.4) 0 1.000
Breast milk
Postb 10 (3.6) 3 (1.0) 3.48 (0.97–12.51) 0.050
Vaginal swab
Prea 2 (0.7) 1 (0.4) 2.08 (0.19–22.88) 0.617
Postc 4 (1.5) 0 – 0.057
Neonatal NPS
Postd 4 (1.5) 2 (0.7) 2.09 (0.39–11.30) 0.442
PR, prevalence ratio. P values from v2 test for prevalence of carriage and Fisher’s exact test for prevalence of resistance.
aIncidence of carriage/resistance at day 0, pre-treatment.
bCumulative incidence of carriage/resistance, i.e. proportion positive at one or more post-treatment visits (days 3, 6, 14 and 28).
cIncidence of carriage/resistance at day 8.
dCumulative incidence of carriage/resistance, i.e. proportion positive at one or more post-treatment visits (days 0, 3, 6, 14 and 28).
eAfter adjusting for baseline imbalance, the difference was not significant (PR"3.11, 95% CI 0.82–11.84, P"0.095).
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post-intervention timepoint during the follow-up as opposed to
individual timepoints used previously for the Gram-positive bac-
teria.8 Other limitations were that we did not have rectal swabs or
stools, the most suitable sample type, especially for E. coli, and it

































































































Figure 3. K. pneumoniae carriage at different timepoints. (a) Maternal NPS carriage. (b) Breast milk carriage. (c) Neonatal NPS carriage. (d) Vaginal
carriage. (e) Maternal NPS resistance. (f) Breast milk resistance. (g) Neonatal NPS resistance. (h) Vaginal resistance.
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Although intra-partum azithromycin has been shown to de-
crease bacterial carriage of Gram-positive bacteria responsible for
maternal and neonatal sepsis (S. aureus, S. pneumoniae and GBS),8,9
we have shown in this study that it does not reduce the carriage of
Enterobacterales. The potential for inducing a short-term increase of
azithromycin resistance among Enterobacterales underscores the
importance of continuous monitoring of resistance in E. coli and
K. pneumoniae as these bacteria are responsible for an important
burden of resistance in hospital- and community-acquired infec-
tions. Future studies should further investigate the effect on resist-
ance beyond the neonatal period and include rectal samples.
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